White Blood Cell Growth Factors
Key Points
Key Points
Primary prophylaxis is recommended for the prevention of febrile neutropenia in patients who are at high risk on the basis of age, medical history, disease characteristics, and myelotoxicity of the chemotherapy regimen.
Dose-dense regimens that require CSFs should be used only within an appropriately designed clinical trial or if supported by convincing efficacy data.
Current recommendations for the management of patients exposed to lethal doses of total-body radiotherapy, but not doses high enough to lead to certain death as a result of injury to other organs, include the prompt administration of CSFs.
Diagnosis
...Diagnosis...
...atient Risk Factors for Febrile Neutropen...
...Patient Risk Factors for Poor Cli...
Treatment for Adult Patients
Treatm...
...ylaxis with a CSF starting with the first cycle an...
...hylaxis with a CSF is recommended for patien...
...not be routinely used for patients...
...t be routinely used as adjunctive treatment wit...
...east cancer and lymphoma] ( EB , H ,...
...ial cancer] ( EB , H , H , M )3336...
...may be used alone, after chemothera...
...should be administered after autolog...
...administered after allogeneic stem-ce...
...ctic CSFs for patients with diffuse aggre...
...tim, filgrastim, tbo-filgrastim, and fil...
...ecommendations for the management of...
Treatment for Pediatric Patients
...Treatm...
...he use of CSFs in pediatric patients will almost...
...ediatric indications in which dose-intens...
...not be used in pediatric patients with nonrelaps...
Table 3. Dosing and Administration of CSFs
...able 3. Dosing and Administration of CSFsH...